Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

15 Feb 2021

Abstract excerpt

Abstract Purpose: G9a histone methyltransferase exerts oncogenic effects in several tumor types and its inhibition promotes anticancer effects. However, the impact on checkpoint inhibitor blockade response and the utility of G9a or its target genes as a biomarker is poorly studied. We aimed to examine whether G9a inhibition can augment the efficacy of checkpoint inhibitor blockade and whether LC3B, a G9a target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33589432
DOI: 10.1158/1078-0432.ccr-20-3463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in MelanomaPMID 33589432Read ↗

Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.Semantic proximity Read ↗

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling the responses of T-cells, myeloid derived suppressor cells and NK cellsSemantic proximity Read ↗

B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.Semantic proximity Read ↗

Mi-2β-targeted inhibition induces immunotherapy response in melanomaSemantic proximity Read ↗

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.Semantic proximity Read ↗

PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunitySemantic proximity Read ↗

Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma ImmunotherapySemantic proximity Read ↗

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeSemantic proximity Read ↗

Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA DataSemantic proximity Read ↗

B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanomaSemantic proximity Read ↗

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylationSemantic proximity Read ↗

Elraglusib (9-ING-41), a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3, and enhances CD8+ T cell cytolytic killing of melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.